InVivo touts experimental hydrogel for spinal cord injuries

March 9, 2011 by MassDevice staff

InVivo Therapeutics Holdings Corp. plans to present data on its injectable hydrogel technology for local, controlled-release drug delivery for treatment of spinal cord injury.

NVIV logo

InVivo Therapeutics Holdings Corp. (OTC:NVIV) is headed to Phoenix for the annual meeting of the American Assn. of Neurological Surgeons.

The Cambridge, Mass.-based company plans to present the latest data on its hydrogel for spinal cord injury and neurosurgical applications.

The technology, designed to address the underlying pathology of SCI, is intended for "sustained release of methylprednisolone sodium succinate," according to InVivo.

The company designed its latest research on the hydrogel to evaluate its potential "to overcome limitations associated with systemic administration of high-dose methylprednisolone, a steroid that is commonly used in the treatment of SCI." Methylprednisolone treatments have been associated with increased risk of infection, delayed wound healing, pneumonia and sepsis, according to InVivo.

The company is also developing a bio-compatible polymer scaffold for which it is hoping to commence a clinical study during the second half of this year.

InVivo, which went public in a reverse merger last October, tapped biomedical engineer Phil Pereira to be its first director of manufacturing in February.